CD38 and myeloid leukemia: We also examined the ability of our 123b-33bcCAR to eliminate specific cell populations including LSCs (CD123+CD34+CD38−) in the PT3 sample and myeloid leukemia bulk disease (CD34variableCD33+) in the PT4 sample (Fig. 3c, d).